April 30 (Reuters) - The U.S. Food and Drug Administration (FDA) has approved granule formulation of Neurocrine Biosciences' drug to treat movement disorders associated with Huntington's disease, the company said on Tuesday. (Reporting by Sruthi Narasimha Chari and Mariam Sunny in Bengaluru; Editing by Alan Barona)